Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Sets Up Development Center at China Subsidiary to Boost Development in Asia
February 10, 2012
- Eisai to Transfer Shares and Equity of its Pharmaceutical Machinery Business Subsidiaries
February 10, 2012
- Nomura Report Recommends Otsuka HD, DSP, Eisai Shares
February 10, 2012
- Mr Takeuchi of Astellas Stresses Importance of IP Strategies in Tie-ups with Bioventures
February 10, 2012
- Teijin Aims for ¥400 Billion in Sales in Healthcare by FY2020
February 9, 2012
- Sales of Ethical Drugs Up 5.3% in December: Crecon Report
February 9, 2012
- Meiji Seika Pharma Begins PII Trial of Schizophrenia Drug Ziprasidone in Japan
February 9, 2012
- Santen Pharmaceutical Apr-Dec Sales Up 5.3% on Steady Growth in Japan and Abroad
February 8, 2012
- Novartis President Mitani Says Diovan Patent Expiry an “Urgent Issue”
February 8, 2012
- Novartis Domestic Sales Up 6% Despite Drop in Diovan
February 8, 2012
- All-Case PMS for Chugai’s Tarceva for NSCLC Lifted
February 8, 2012
- Janssen Files NDA for Anti-HIV Agent Edurant in Japan
February 8, 2012
- JCR Hopes to Build Delivery Network, Boost Product Promotion in Collaboration with Medipal: Chairman Ashida
February 7, 2012
- DSP President Tada Says Steady Shift to Latuda Seen in US
February 7, 2012
- JCR to Push Joint Development with GSK, Including New Biopharmaceuticals
February 7, 2012
- Apr-Dec Sales Rise 7.4% due to Vidaza: Nippon Shinyaku
February 7, 2012
- Apr-Dec Sales Up 1.9% Driven by Artz: Kaken
February 7, 2012
- Astellas to Establish New Global Human Resources Committee on April 1
February 7, 2012
- Takeda Announces US Launch of Combination Hypertension Treatment Edarbyclor
February 7, 2012
- Sanofi-aventis Initiates ALOHA 2 Study of Lantus Plus DPP-4 Inhibitors for Type 2 Diabetes
February 7, 2012
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…